Cargando…

Clinical effects of Cariprazine and their relationship with polymorphisms of dopamine and serotonin receptors: preliminary results from a prospective study on schizophrenia and bipolar disorder

INTRODUCTION: Cariprazine (CAR) is a D2, D3, 5HT1A receptor partial agonist and a 5HT2A, 5HT2B antagonist, used to treat Schizophrenia and Bipolar disorder. Interindividual variability in therapeutic and side effects of antipsychotics is difficult to predict, due to non-genetic and genetic factors....

Descripción completa

Detalles Bibliográficos
Autores principales:	De Pieri, M., Dyrmishi, E., Bolla, E., Preve, M., Colombo, R.A., Traber, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566989/ http://dx.doi.org/10.1192/j.eurpsy.2022.1746

Ejemplares similares

Case Report: Long-Acting Oral Cariprazine
por: Dyrmishi, Emanuela, et al.
Publicado: (2022)

Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine
por: De Pieri, Marco, et al.
Publicado: (2023)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts, Rona Jeannie, et al.
Publicado: (2016)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine
por: Werner, Felix-Martin, et al.
Publicado: (2015)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
por: Periclou, Antonia, et al.
Publicado: (2019)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials
por: Mcintyre, R., et al.
Publicado: (2022)

CENTRAL DOPAMINE AND SEROTONIN TURNOVER IN SCHIZOPHRENIA
por: Pandey, R.S., et al.
Publicado: (1987)

Cariprazine add-on for resistant bipolar depression: preliminary results from an italian real-world experience
por: Martiadis, V., et al.
Publicado: (2023)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel, Thomas
Publicado: (2021)

Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy
por: Tarzian, Martin, et al.
Publicado: (2023)

Cariprazine’s efficacy in treating depressive symptoms – pooled data from schizophrenia, bipolar depression and major depression trials
por: McIntyre, R. S., et al.
Publicado: (2023)

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor
por: Frank, Annika, et al.
Publicado: (2018)

Benzodiazepine use during cariprazine treatment in acute schizophrenia
por: Correll, C., et al.
Publicado: (2022)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
por: Montgomery, Adam, et al.
Publicado: (2023)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity
por: Kehr, Jan, et al.
Publicado: (2018)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series
por: Bajouco, Miguel, et al.
Publicado: (2022)

Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2014)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes, Jose M, et al.
Publicado: (2021)

Cariprazine pharmacokinetics
Publicado: (2022)

The gordian knot of overlapping symptoms between dissociative identity disorder and borderline personality disorder, the need for a clear cut: A case report
por: Romanos, I., et al.
Publicado: (2021)

A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2013)

Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
por: Rancans, Elmars, et al.
Publicado: (2022)

Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
por: Morozov, Petr, et al.
Publicado: (2022)

Cariprazine exerts antimanic properties and interferes with dopamine D(2) receptor β-arrestin interactions
por: Gao, Yonglin, et al.
Publicado: (2015)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction
por: Rodriguez Cruz, Jose, et al.
Publicado: (2021)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Combined use of clozapine and cariprazine in treatment-resistant schizophrenia, is it a good choice?
por: Darriba, H. Becerra
Publicado: (2021)

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018)

Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study
por: Earley, Willie R., et al.
Publicado: (2019)

Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters
por: Hagino, Y, et al.
Publicado: (2011)

Cariprazine Exhibits Anxiolytic and Dopamine D(3) Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
por: Duric, Vanja, et al.
Publicado: (2017)

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)
por: Nakamura, Tadakatsu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h71jk1n3ffan3ba0jg7ujqjj6p